-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $21

Benzinga·09/09/2026 13:33:52
語音播報
RBC Capital analyst Brian Abrahams maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $29 to $21.